UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049985
Receipt number R000056896
Scientific Title Proposed cut-off CA19-9 values for detection of pancreatic cancer in patients with poorly glycemic controlled diabetes: a real-world study
Date of disclosure of the study information 2023/01/07
Last modified on 2024/01/09 12:01:00

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Proposed cut-off CA19-9 values for detection of pancreatic cancer in patients with poorly glycemic controlled diabetes: a real-world study

Acronym

Proposed cut-off CA19-9 values for detection of pancreatic cancer in patients with poorly glycemic controlled diabetes: a real-world study

Scientific Title

Proposed cut-off CA19-9 values for detection of pancreatic cancer in patients with poorly glycemic controlled diabetes: a real-world study

Scientific Title:Acronym

Proposed cut-off CA19-9 values for detection of pancreatic cancer in patients with poorly glycemic controlled diabetes: a real-world study

Region

Japan


Condition

Condition

diabetes mellitus, pancreatic cancer

Classification by specialty

Hepato-biliary-pancreatic medicine Endocrinology and Metabolism

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To determine cut-off CA19-9 values for detection of pancreatic cancer in poorly glycemic controlled patients with diabetes, and its sensitivity and specificity

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Differences in CA19-9 values between patients with and without pancreatic cancer among patients with poorly glycemic controlled diabetes

Key secondary outcomes

Cut-off CA19-9 values for detection of pancreatic cancer in poorly glycemic controlled patients with diabetes, and its sensitivity and specificity


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Inpatients with diabetes mellitus
Patients with measured CA19-9 level
Patients who have undergone abdominal echocardiography or abdominal CT
Patients who could be evaluated for pancreatic cancer by examining abdominal symptoms and jaundice in six months after hospitalization

Key exclusion criteria

Patients who refuse participating in research in response to opt-out notification
Patients with malignant tumors requiring treatment currently

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name Taku
Middle name
Last name Yamada

Organization

Saiseikai Yokohamashi Nanbu Hospital

Division name

Diabetes and Endocrinology

Zip code

234-0054

Address

3-2-10 Konandai, Konan-ku, Yokohama

TEL

0458321111

Email

hyyoh16y@yahoo.co.jp


Public contact

Name of contact person

1st name Taku
Middle name
Last name Yamada

Organization

Saiseikai Yokohamashi Nanbu Hospital

Division name

Diabetes and Endocrinology

Zip code

234-0054

Address

3-2-10 Konandai, Konan-ku, Yokohama

TEL

0458321111

Homepage URL

https://www.nanbu.saiseikai.or.jp/media/tounai2019D31.pdf

Email

hyyoh16y@yahoo.co.jp


Sponsor or person

Institute

Saiseikai Yokohamashi Nanbu Hospital

Institute

Department

Personal name

yamada taku


Funding Source

Organization

Saiseikai Yokohamashi Nanbu Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Saiseikai Yokohamashi Nanbu Hospital

Address

3-2-10 Konandai, Konan-ku, Yokohama

Tel

0458321111

Email

hyyoh16y@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 01 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

1060

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2019 Year 11 Month 12 Day

Date of IRB

2019 Year 11 Month 12 Day

Anticipated trial start date

2021 Year 04 Month 16 Day

Last follow-up date

2023 Year 01 Month 11 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This is a retrospective cohort study, with no intervention.


Management information

Registered date

2023 Year 01 Month 07 Day

Last modified on

2024 Year 01 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056896


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name